Risk of dissolution failure prompts recall of potassium chloride ER capsules

Glenmark Pharmaceuticals is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K that are used for the treatment of hypokalemia. The product is being recalled because of failed dissolution of the capsules, which may cause hyperkalemia and potentially lead to cardiac arrhythmias, severe muscle weakness, and death. To date, there have been no reports of hyperkalemia or serious adverse events related to this recall.